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OBJECTIVES The aim of this study was to evaluate the impact of smoking in patients with left ventricular
dysfunction.
BACKGROUND The impact of smoking in patients with left ventricular dysfunction has not been well-studied.
METHODS We compared the incidence of death, hospitalization due to heart failure and myocardial
infarction (MI) in current smokers to ex-smokers of #2 years and ex-smokers of .2 years
duration to never-smokers among participants of the Study Of Left Ventricular Dysfunction
(SOLVD) Prevention and Intervention trials. Participants all had left ventricular ejection
fraction (LVEF) ,35% and follow-up was over a mean of 41 months.
RESULTS Complete smoking status and outcome data were available in 6,704 subjects. There were
1,562 current smokers, 1,317 ex-smokers of #2 years, 2,354 ex-smokers of .2 years and
1,471 never-smokers. After adjusting for baseline differences of age, LVEF, race and etiology
of heart failure, current smoking was associated with a significantly increased all-cause
mortality (relative risk [RR]: 1.41, 95% confidence interval [CI]: 1.25 to 1.58, p , 0.001)
compared with ex-smokers and never-smokers. The incidence of death or recurrent
congestive heart failure requiring hospitalization or MI was significantly greater (RR: 1.39,
95% CI: 1.26 to 1.52, p , 0.001) in current smokers compared with ex-smokers and
never-smokers. There were no significant differences in the number of deaths or hospital-
izations due to heart failure between ex-smokers and never-smokers. This effect was
consistent across both the SOLVD Prevention and Treatment trials.
CONCLUSIONS Current smoking is a powerful independent predictor of morbidity (recurrent heart failure and
MI) and mortality in patients with left ventricular dysfunction. Quitting smoking appears to
have a substantial and early effect (within two years) on decreasing morbidity and mortality
in patients with left ventricular dysfunction, which is at least as large as proven drug
treatments recommended in patients with left ventricular dysfunction. (J Am Coll Cardiol
2001;37:1677–82) © 2001 by the American College of Cardiology
Cigarette smoking is the major known modifiable risk factor
for coronary heart disease in both men and women. Ciga-
rette smoking substantially increases the risk of a first
myocardial infarction (MI) in men and women and is
responsible for a 70% excess death rate from coronary heart
disease in general (1). There is considerable overlap between
the effects of cigarette smoking on the cardiovascular system
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and the pathophysiologic mechanisms of congestive heart
failure (CHF). The pathophysiology of chronic heart failure
includes structural cardiac damage that adversely affects
systolic or diastolic function with compensatory hemody-
namic and neurohormonal mechanisms leading to periph-
eral vasoconstriction, sodium retention and endothelial
dysfunction (2). The constituents of inhaled tobacco dam-
age the cardiovascular system by numerous mechanisms,
including endothelial dysfunction, platelet dysfunction, in-
creased coagulation, increased heart rate, blood pressure,
increased myocardial oxygen demand and vasoconstriction
(3,4). Therefore, smoking may be expected to have multiple
adverse effects in patients with CHF.
Cigarette smoking increases heart rate and blood pres-
sure, thereby increasing myocardial oxygen consumption; it
increases carboxyhemoglobin, which has a negative inotrop-
ic effect, and increases left ventricular end diastolic pressure
(4). Smoking is a major risk factor for the development of
coronary artery disease, which is the major cause of heart
failure. In addition, smoking is a strong predictor for the
development of heart failure (5), of sudden death for those
who have CHF (6) and of mortality in patients with
idiopathic dilated cardiomyopathy (7).
Smoking cessation is universally recommended in pa-
tients with coronary artery disease and CHF. However, the
effect of smoking cessation on outcome in patients with
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CHF is largely unknown. Compared with individuals who
had never smoked, we examined the impact of current
smoking, former smoking within two years (ex-smokers of
#2 years) or more than two years (ex-smokers of .2 years)
of quitting before study entry on all-cause mortality, hospi-
talizations due to heart failure, hospitalizations due to MI
and a composite outcome of all-cause mortality or hospital-
izations due to heart failure among the participants of the
Studies Of Left Ventricular Dysfunction (SOLVD) Treat-
ment (8) and Prevention (9) trials.
METHODS
The SOLVD study consisted of two multicenter double-
blind randomized placebo-controlled trials of patients with
left ventricular ejection fraction (LVEF) ,0.35. Details of
the patient characteristics, design and results have been
published previously (8–10). The trials evaluated the effects
of the angiotensin-converting enzyme inhibitor enalapril on
morbidity and mortality in patients with (9) and without (8)
overt heart failure. In the SOLVD Treatment trial (9),
2,569 patients were followed for a mean of 41 months, and
in the SOLVD Prevention trial (8), 4,228 patients were
followed for a mean of 37 months. In the Treatment trial,
enalapril significantly reduced mortality and hospitalization
for heart failure (9). In the Prevention trial, enalapril
significantly reduced the incidence of heart failure compared
with placebo (8). The SOLVD study was approved by each
center’s institutional review board, and each patient pro-
vided written informed consent.
Statistical analysis. Continuous variables were summa-
rized using means and standard deviations. Proportions
were used to summarize discrete variables. Former smokers
were divided into two categories on the basis of length of
duration since quitting smoking, and the cut-point was
taken to be two years (i.e., ex-smokers of #2 years and
ex-smokers of .2 years). These categories were chosen as a
compromise between earlier literature that reported that, in
men and women without CHF, it takes approximately three
years for an ex-smoker to assume a similar risk of MI to a
never-smoker (11,12); the categories were also chosen
because of the desire to have roughly equal-sized groups of
more than 1,000 patients to allow for appropriate power for
statistical analyses.
The effect of smoking on mortality, hospitalization for
CHF or MI was assessed after adjusting for a prespecified
set of baseline characteristics of age, weight, gender, blood
pressure at entry, heart rate at entry, previous MI, previous
revascularization, history of hypertension, history of diabe-
tes, history of heart failure, New York Heart Association
class, ejection fraction, treatment allocation, etiology and
cardiothoracic ratio using Cox proportional hazards model
(13). A significance level of 0.05 (two-sided) was employed
in assessing statistical significance. The effect of smoking
and ex-smoking in the model was expressed in terms of
relative risk (RR) and 95% confidence interval (CI) and
adjusted for the prespecified baseline variables described
earlier.
RESULTS
Complete smoking status data were available in 6,704 of the
6,788 subjects reported in the SOLVD trials (8,9). There
were 1,562 current smokers, 1,317 ex-smokers of #2 years,
2,354 ex-smokers of .2 years and 1,471 never-smokers.
Both current smokers and ex-smokers of #2 years were
younger than ex-smokers of .2 years and never-smokers
(Table 1). More men were current smokers as compared
with women. A higher proportion of current smokers had
an ischemic cause to their CHF compared with never-
smokers. Likewise, a greater proportion of current smokers
had a history of a previous MI compared with never-
smokers. A number of important baseline differences existed
between current and never-smokers. Smokers were more
likely to be men, have ischemic heart disease, be nondiabetic
and not have a history of hypertension.
Current smokers versus current nonsmokers. Substan-
tially more current smokers died overall (RR: 1.41, p ,
0.001), died from heart failure (RR: 1.31, p 5 0.017), were
admitted to the hospital for heart failure (RR: 1.21, p 5
0.006) or experienced an MI (RR: 1.51, p , 0.001)
compared with current nonsmokers (Tables 2 and 3, Fig. 1).
Current smoking was associated with an increased risk of
death due to heart failure (RR: 1.41, p 5 0.009) in the
Treatment trial and an increased risk of MI (RR: 1.77, p ,
0.001) in the Prevention trial. Current smoking was asso-
ciated with a substantially increased risk of dying or being
hospitalized due to heart failure or an MI (RR: 1.39, p ,
0.001), and this effect was consistent across the Treatment
(RR: 1.26, p , 0.001) and Prevention (RR: 1.53, p ,
0.001) trials.
Current smokers versus ex-smokers of <2 years versus
ex-smokers of >2 years versus never-smokers. Current
smokers had a substantially greater all-cause mortality rate
(RR: 1.40, p , 0.001) compared with never-smokers
(Tables 2 and 4, Fig. 1). This effect was consistent across the
Prevention (RR: 1.37, p 5 0.007) and Treatment (RR:
1.38, p 5 0.001) trials. There were no significant differences
in the all-cause mortality rate between ex-smokers of any
duration and never-smokers. Overall, there was a modest
increased risk of death due to progressive heart failure in
current smokers (RR: 1.28, p 5 0.079) compared with
never-smokers. This effect was due to the increased risk in
Abbreviations and Acronyms
CHF 5 congestive heart failure
CI 5 confidence interval
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
RR 5 relative risk
SOLVD 5 Studies Of Left Ventricular Dysfunction
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the Treatment trial (RR: 1.34, p 5 0.071). There was no
significant difference in the number of heart failure deaths
between never-smokers and ex-smokers #2 years or ex-
smokers of .2 years duration. Overall, current smokers
were at an increased risk of hospitalization due to heart
failure (RR: 1.20, p 5 0.03) compared with never-smokers.
This effect was largely due to the increase in the number of
hospitalizations due to heart failure in the Prevention trial
(RR: 1.42, p 5 0.016). Ex-smokers of any duration had
similar rates of heart failure hospitalizations compared with
never-smokers. Overall, more current smokers experienced
an MI (RR: 1.43, p 5 0.021) compared with never-
smokers. This effect was largely due to the increased risk of
MI among current smokers in the Prevention trial (RR:
1.57, p 5 0.019). There was no significant difference in the
risk of MI among never-smokers and ex-smokers of any
duration in either of the trials. Current smokers were at
substantially increased risk of dying or being hospitalized for
heart failure or MI (RR: 1.39, p , 0.001) compared with
never-smokers, while ex-smokers of any duration were at a
similar risk to never-smokers of dying or being hospitalized
for heart failure or MI.
The main adverse effect of current smoking (versus ex-
and never-smoking) was accounted for by the increased
event rate in those patients with an ischemic heart failure
etiology (ischemic etiology: adjusted RR [95% CI] for
mortality or MI or heart failure hospitalization in smokers
vs. ex-smokers of #2 years vs. ex-smokers of .2 years vs.
never-smokers was 1.45 [1.24 to 1.7] vs. 1.09 [0.92 to 1.29]
vs. 1.00 [0.87 to 1.16] vs. 1; nonischemic etiology: 1.13
[0.89 to 1.43] vs. 1.05 [0.80 to 1.37] vs. 0.91 [0.72 to 1.15]
vs. 1).
DISCUSSION
Main findings. There were two main findings illustrated
by this study. First, current smoking was associated with a
substantially increased risk of death, hospitalization due to
heart failure and MI in both Prevention and Treatment trial
patients. Second, patients who stopped smoking had a lower
risk of death, hospitalization due to heart failure and MI
that was largely similar to that of patients who had never
smoked.
Reduced risk associated with smoking cessation. Patients
with reduced LVEF with or without symptoms of CHF
who had never smoked or who had quit smoking had a 30%
lower risk of dying over 41 months compared with patients
who were current smokers after adjusting for baseline
Table 1. Baseline Characteristics (Combined Trials)
Variables
Never-Smoker
(n 5 1,471)
Ex-Smoker
>2 years
(n 5 2,354)
Ex-Smokers
<2 years
(n 5 1,317)
Current Smoker
(n 5 1,562)
Mean 6 SD
Age (yrs)* 62.4 6 10.67 62.3 6 8.9 56.7 6 9.9 56.1 6 10.0
Weight (kg) 78.8 6 15.9 82.6 6 14.6 81.1 6 15.8 79.6 6 15.8
Systolic BP (mm Hg)* 125.8 6 17.2 126.9 6 17.2 122.7 6 16.4 124.5 6 16.7
Diastolic BP (mm Hg)* 77.3 6 10.4 77.6 6 9.8 77.4 6 9.5 77.8 6 9.9
LVEF 0.24 6 0.09 0.26 6 0.10 0.26 6 0.09 0.25 6 0.09
Heart rate (beats/min)* 77.3 6 13.3 75.2 6 12.7 77.2 6 13.3 78.4 6 12.8
Proportion (%)
Men† 71.9 91.8 85.7 88.9
NYHA-FC
1 45.2 45.8 48.1 44.2
2 41.4 42.7 39.6 43.5
3 or 4 13.4 11.5 12.2 12.3
CT ratio .0.50* 54.0 44.5 46.4 41.8
Heart failure etiology*
Ischemic 71.1 82.8 82.8 76.6
Other 28.9 17.2 17.2 23.3
History of
MI* 64.7 79.7 79.0 73.0
Angina* 48.3 60.2 58.8 60.6
Diabetes mellitus* 23.5 20.7 15.6 15.7
Hypertension* 43.5 41.0 34.5 36.2
Medications
Digitalis* 35.1 35.1 30.0 30.4
Diuretics* 46.9 43.3 38.5 41.5
Antiplatelet* 42.2 47.6 52.5 43.2
Study drug
Enalapril 49.8 50.1 50.4 49.7
Placebo 50.2 49.9 49.6 50.3
Overall comparison: *p # 0.001; †0.001 , p # 0.01.
BP 5 blood pressure; CT ratio 5 cardiothoracic ratio; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction;
NYHA-FC 5 New York Heart Association functional class.
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differences. There was no significant difference in mortality
between patients who had never smoked compared with
ex-smokers of any duration. This 30% lower mortality
observed in current nonsmokers (ex- or never-smokers)
compared with current smokers is of the same magnitude as
that of enalapril treatment (19% mortality reduction) com-
pared with placebo (9) and metoprolol treatment (34%
mortality reduction) compared with placebo (14) and spi-
ronolactone treatment (30% mortality reduction) compared
with placebo (15). Yet smoking cessation has not been
emphasized as an integral part of the management of
patients with heart failure.
The main adverse effect of current smoking was ac-
counted for by the increased event rate in those patients
with ischemic heart disease. The reasons for the apparent
lack of association of current smoking with adverse outcome
in the nonischemic patients were unclear, and this subgroup
analysis should be interpreted with caution, as there were
only 1,428 patients without ischemia compared with 4,080
patients with ischemia. As well, previous reports have
suggested that current smoking is associated with an in-
creased risk of mortality in patients with idiopathic dilated
cardiomyopathy (7).
Time frame of reduced risk. Earlier reports have sug-
gested that, in men and women without CHF, it takes
approximately three years for an ex-smoker to assume a
similar risk for MI to a never-smoker (11,12). Our study
suggests that, among smokers with CHF who quit smoking,
the risk of recurrent CHF or MI is substantially decreased
in less than three years. This almost immediate decrease in
Table 2. Actual Number of Events by Smoking Status and Trial
Combined Trials
n (%)
Treatment Trial
n (%)
Prevention Trial
n (%)
Overall mortality
Never smoker 355 (24.13) 212 (35.69) 143 (16.31)
Ex-smoker .2 yr 519 (22.05) 318 (35.06) 201 (13.89)
Ex-smoker #2 yr 285 (21.64) 172 (36.99) 113 (13.26)
Current smoker 423 (27.08) 243 (42.78) 180 (18.11)
CHF mortality
Never smoker 114 (7.75) 82 (13.80) 32 (3.65)
Ex-smoker .2 yr 160 (6.80) 107 (11.80) 53 (3.66)
Ex-smoker #2 yr 75 (5.69) 51 (10.97) 24 (2.82)
Current smoker 112 (7.17) 82 (14.44) 30 (3.02)
CHF hospitalization
Never smoker 300 (20.39) 206 (34.68) 94 (10.72)
Ex-smoker .2 yr 410 (17.42) 264 (29.11) 146 (10.09)
Ex-smoker #2 yr 210 (15.95) 128 (27.53) 82 (9.62)
Current smokers 296 (18.95) 178 (31.34) 118 (11.87)
MI hospitalization
Never smoker 76 (5.17) 29 (4.88) 47 (5.36)
Ex-smoker .2 yr 131 (5.56) 55 (6.06) 76 (5.25)
Ex-smoker #2 yr 66 (5.01) 30 (6.45) 36 (4.23)
Current smoker 117 (7.49) 38 (6.69) 79 (7.95)
Mortality or CHF
hospitalization or MI
Never smokers 549 (37.32) 318 (53.54) 231 (26.34)
Ex-smokers .2 yr 809 (34.37) 471 (51.93) 338 (23.36)
Ex-smoker #2 yr 428 (32.50) 239 (51.40) 189 (22.18)
Current smokers 651 (41.68) 341 (60.04) 310 (31.19)
CHF 5 congestive heart failure; MI 5 myocardial infarction.
Table 3. Relative Risk of Current Smokers Versus Current Nonsmokers
Both Trials Treatment Trial Prevention Trial
RR (95% CI) p Value RR (95% CI) p Value RR (95% CI) p Value
Mortality 1.41 (1.25, 1.58) ,0.001 1.34 (1.15, 1.56) ,0.001 1.47 (1.23, 1.75) ,0.001
CHF mortality 1.31 (1.05, 1.63) 0.017 1.41 (1.09, 1.83) 0.009 1.04 (0.69, 1.57) 0.850
CHF hospitalization 1.21 (1.07, 1.38) 0.006 1.11 (0.93, 1.32) 0.238 1.33 (1.07, 1.66) 0.009
MI 1.51 (1.21, 1.88) ,0.001 1.13 (0.77, 1.65) 0.526 1.77 (1.33, 2.32) ,0.001
Mortality or CHF
hospitalization or MI
1.39 (1.26, 1.52) ,0.001 1.26 (1.11, 1.43) ,0.001 1.53 (1.33, 1.75) ,0.001
RR for current nonsmokers 5 1. RR was adjusted for age, weight, gender, blood pressure, heart rate, history of previous MI, revascularization, hypertension, diabetes, heart failure,
NYHA-FC, LVEF, treatment allocation, etiology and cardiothoracic ratio.
CHF 5 congestive heart failure; CI 5 confidence interval; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; NYHA-FC 5 New York Heart Association
functional class; RR 5 relative risk.
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the recurrence of CHF could, in part, be explained by the
expected decrease of detrimental hemodynamic effects as-
sociated with smoking. Cigarette smoking in patients with
New York Heart Association class III heart failure increases
heart rate and systemic blood pressure as well as systemic
and pulmonary vascular resistance, that is, increased ven-
tricular afterload. Cigarette smoking increases oxygen de-
mand and decreases myocardial oxygen supply, which has
important negative consequences for myocardial oxygen
balance (16).
Figure 1. Relative risk (RR) of events by smoking status adjusted for baseline characteristics. RR never-smoker 5 1. *p , 0.05, current smokers versus
ex-smokers of #2 years versus ex-smokers of .2 years versus never-smokers. Open box 5 hospitalization due to heart failure; hatched box 5 myocardial
infarction; solid box 5 mortality.
Table 4. Mortality and Morbidity: Current Smoking, Ex-Smoking #2 Years, Ex-Smoking .2 Years Versus Never Smoking
Combined
Trials
Treatment
Trial
Prevention
Trial
RR (95% CI) p Value RR (95% CI) p Value RR (95% CI) p Value
Overall mortality
Never smoker 1 1 1
Ex-smoker .2 yr 0.95 (0.82, 1.09) 0.4303 0.98 (0.81, 1.17) 0.7786 0.86 (0.69, 1.07) 0.187
Ex-smoker #2 yr 1.10 (0.94, 1.29) 0.2442 1.17 (0.95, 1.44) 0.1301 1.00 (0.78, 1.29) 0.999
Current smoker 1.40 (1.21, 1.63) ,0.001 1.38 (1.14, 1.68) 0.0011 1.37 (1.09, 1.72) 0.007
CHF mortality
Never smoker 1 1 1
Ex-smoker .2 yr 0.95 (0.74, 1.22) 0.712 0.90 (0.67, 1.22) 0.508 1.0 (0.64, 1.57) 0.998
Ex-smoker #2 yr 1.00 (0.74, 1.35) 0.998 1.00 (0.70, 1.43) 0.993 1.03 (0.60, 1.78) 0.917
Current smoker 1.28 (0.97, 1.68) 0.079 1.34 (0.98, 1.87) 0.071 1.05 (0.62, 1.76) 0.860
CHF hospitalization
Never smoker 1 1 1
Ex-smoker .2 yr 0.98 (0.84, 1.14) 0.7680 0.91 (0.75, 1.10) 0.3390 1.04 (0.80, 1.35) 0.784
Ex-smoker #2 yr 1.01 (0.84, 1.22) 0.8855 0.91 (0.73, 1.15) 0.4406 1.19 (0.88, 1.62) 0.263
Current smoker 1.20 (1.01, 1.42) 0.0344 1.04 (0.84, 1.29) 0.7054 1.42 (1.07, 1.88) 0.016
MI hospitalization
Never smoker 1 1 1
Ex-smoker .2 yr 0.95 (0.71, 1.27) 0.731 0.97 (0.61, 1.54) 0.893 0.92 (0.64, 1.34) 0.664
Ex-smoker #2 yr 0.90 (0.64, 1.27) 0.550 1.10 (0.65, 1.86) 0.737 0.77 (0.49, 1.20) 0.250
Current smoker 1.43 (1.05, 1.93) 0.021 1.14 (0.69, 1.90) 0.602 1.57 (1.08, 2.29) 0.019
Mortality or hospitalization
due to heart failure or MI
Never smoker 1 1 1
Ex-smoker .2 yr 0.97 (0.87, 1.09) 0.623 0.98 (0.85, 1.14) 0.822 0.91 (0.77, 1.08) 0.292
Ex-smoker #2 yr 1.06 (0.93, 1.21) 0.409 1.09 (0.91, 1.29) 0.361 1.10 (0.83, 1.23) 0.951
Current smoker 1.39 (1.23, 1.57) ,0.001 1.28 (1.09, 1.50) 0.003 1.47 (1.23, 1.75) ,0.001
RR for never-smokers 5 1. RR was adjusted for age, weight, gender, blood pressure, heart rate, history of previous MI, revascularization, hypertension, diabetes, heart failure,
NYHA-FC, LVEF, treatment allocation, etiology and CT ratio.
CHF 5 congestive heart failure; CI 5 confidence interval; CT ratio 5 cardiothoracic ratio; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction;
NYHA-FC 5 New York Heart Association functional class; RR 5 relative risk.
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Study limitations. The effects of smoking cessation in
patients with left ventricular dysfunction on morbidity and
mortality in this study were assessed by observational
techniques only, which has inherent limitations. Our study
was consistent with the vast majority of literature, which has
utilized observational techniques to evaluate the association
between smoking cessation and morbidity and mortality.
We did, however, adjust our analyses for potential prognos-
tically important differences between the groups. We did
not collect any information on follow-up on smoking status
after entry into the SOLVD trials. Therefore, our study may
have underestimated the magnitude of the association be-
tween current smoking and adverse outcome, given that the
individuals we categorized as ex-smokers may have subse-
quently resumed smoking.
Conclusions. Current smoking is a powerful independent
predictor of morbidity and mortality in patients with re-
duced left ventricular systolic function with and without
symptoms of heart failure. Quitting smoking is associated
with the accomplishment of a very expeditious decrease in
morbidity and mortality, which is similar in magnitude to
the effect of an appropriate angiotensin-converting enzyme,
beta-adrenergic blocking agent or spironolactone use in
patients with reduced left ventricular systolic function and
symptoms of heart failure, yet little emphasis has been
placed on smoking cessation strategies in these patients.
Universal introduction of smoking cessation strategies in
patients with reduced left ventricular systolic function, with
or without symptoms of CHF, are of critical importance
and should be adopted as vigorously as proven medical
therapy.
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